Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy

INTRODUCTION: Altered gastrointestinal (GI) barrier integrity and subsequent microbial translocation may contribute to immune activation in HIV infection. We have reported that rosuvastatin improved several markers of immune activation in HIV+ participants, but the effect of statin treatment on mark...

Descripción completa

Detalles Bibliográficos
Autores principales: Funderburg, Nicholas T., Boucher, Morgan, Sattar, Abdus, Kulkarni, Manjusha, Labbato, Danielle, Kinley, Bruce I., McComsey, Grace A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pathogens and Immunity 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972492/
https://www.ncbi.nlm.nih.gov/pubmed/27500282
http://dx.doi.org/10.20411/pai.v1i1.124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972492/
https://www.ncbi.nlm.nih.gov/pubmed/27500282
http://dx.doi.org/10.20411/pai.v1i1.124

Ejemplares similares